[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100336867":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":58,"centralContacts":62,"locations":70,"responsibleParty":350,"collaborators":51,"id":352,"slug":353,"hasResults":354,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":51,"eligibilityCriteria":358,"healthyVolunteers":354,"sex":359,"minAge":360,"maxAge":51,"enrollmentInfo":361,"targetDuration":51,"studyType":364,"phases":365,"briefSummary":367,"conditions":368,"keywords":51,"overallStatus":97,"whyStopped":51,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":382},{"fullName":5,"class":6},"Imugene Limited","INDUSTRY",[8,16,20,24,28,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1 Dose Escalation: Azer-cel Dose Level 1","EXPERIMENTAL","Azer-cel, 3 x 10\\^5 CAR T cells per kilogram (kg) body weight.\n\nRoute of Administration: Intravenous infusion",[13,14,15],"Biological: Azer-cel","Drug: Fludarabine","Drug: Cyclophosphamide",{"label":17,"type":10,"description":18,"interventionNames":19},"Phase 1 Dose Escalation: Azer-cel Dose Level 2","Azer-cel, 1 x 10\\^6 CAR T cells per kg body weight.\n\nRoute of Administration: Intravenous infusion",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Phase 1 Dose Escalation: Azer-cel Dose Level 3a","Azer-cel, 3 x 10\\^6 CAR T cells per kg body weight.\n\nRoute of Administration: Intravenous infusion",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Phase 1 Dose Escalation: Azer-cel Dose Level 4","Azer-cel, 6 x 10\\^6 CAR T cells per kg body weight as 2 administrations of 3 x 10\\^6 CAR T cells per kg body weight on Day 0 and Day 10.\n\nRoute of Administration: Intravenous infusion",[13,14,15],{"label":29,"type":10,"description":30,"interventionNames":31},"Phase 1 Dose Escalation: Azer-cel Dose Level 4b","Azer-cel, 500 x 10\\^6 CAR T cells (flat dose).\n\nRoute of Administration: Intravenous infusion",[13,14,15],{"label":33,"type":10,"description":34,"interventionNames":35},"Phase 1B Dose Expansion: Azer-cel","Azer-cel will be administered at a dose level established in Phase 1.\n\nRoute of Administration: Intravenous infusion",[13,14,15,36],"Drug: IL-2",[38,46,52,55],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"BIOLOGICAL","Azer-cel","Infusion of Allogeneic Anti-CD19 CAR T cells",[9,17,21,25,29,33],[44,45],"Allogeneic Anti-CD19 CAR T cells","PBCAR0191",{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"DRUG","Fludarabine","Specified dose on specified days",[9,17,21,25,29,33],null,{"type":47,"name":53,"description":49,"armGroupLabels":54,"otherNames":51},"Cyclophosphamide",[9,17,21,25,29,33],{"type":47,"name":56,"description":49,"armGroupLabels":57,"otherNames":51},"IL-2",[33],[59],{"name":60,"affiliation":5,"role":61},"John Byon, MD, PhD","STUDY_CHAIR",[63,68],{"name":64,"role":65,"phone":66,"phoneExt":51,"email":67},"Imugene Clinical Team","CONTACT","+1 984 245 0082","info@imugene.com",{"name":64,"role":65,"phone":69,"phoneExt":51,"email":67},"+61 2 9423 0881",[71,85,95,112,127,137,151,165,171,181,195,204,214,224,234,248,262,271,285,300,312,325,338],{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":51},"Banner MD Anderson Cancer Center","COMPLETED","Gilbert","Arizona","85234","United States","US",{"type":80,"coordinates":81},"Point",[82,83],-111.78903,33.35283,{"lat":83,"lon":82},{"facility":86,"status":73,"city":87,"state":88,"zip":89,"country":77,"countryCode":78,"cosmosGeoPoint":90,"geoPoint":94,"contacts":51},"City of Hope","Duarte","California","91010",{"type":80,"coordinates":91},[92,93],-117.97729,34.13945,{"lat":93,"lon":92},{"facility":96,"status":97,"city":98,"state":99,"zip":100,"country":77,"countryCode":78,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"H. Lee Moffitt Cancer Center","RECRUITING","Tampa","Florida","33612",{"type":80,"coordinates":102},[103,104],-82.45843,27.94752,{"lat":104,"lon":103},[107,109],{"name":108,"role":65,"phone":51,"phoneExt":51,"email":51},"Clinical Research",{"name":110,"role":111,"phone":51,"phoneExt":51,"email":51},"Bijal Shah, MD","PRINCIPAL_INVESTIGATOR",{"facility":113,"status":97,"city":114,"state":115,"zip":116,"country":77,"countryCode":78,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Winship Cancer Institute Emory University","Atlanta","Georgia","30322",{"type":80,"coordinates":118},[119,120],-84.38798,33.749,{"lat":120,"lon":119},[123,125],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},"Clinical Trials",{"name":126,"role":111,"phone":51,"phoneExt":51,"email":51},"Edmund Waller, MD",{"facility":128,"status":97,"city":114,"state":115,"zip":129,"country":77,"countryCode":78,"cosmosGeoPoint":130,"geoPoint":132,"contacts":133},"Northside Hospital Cancer Institute","30342",{"type":80,"coordinates":131},[119,120],{"lat":120,"lon":119},[134,135],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":136,"role":111,"phone":51,"phoneExt":51,"email":51},"Scott Solomon, MD",{"facility":138,"status":97,"city":139,"state":140,"zip":141,"country":77,"countryCode":78,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"University of Maryland","Baltimore","Maryland","21201",{"type":80,"coordinates":143},[144,145],-76.61219,39.29038,{"lat":145,"lon":144},[148,149],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":150,"role":111,"phone":51,"phoneExt":51,"email":51},"Jean Yared, MD",{"facility":152,"status":97,"city":153,"state":154,"zip":155,"country":77,"countryCode":78,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Tufts Medical Center","Boston","Massachusetts","02111",{"type":80,"coordinates":157},[158,159],-71.05977,42.35843,{"lat":159,"lon":158},[162,163],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":164,"role":111,"phone":51,"phoneExt":51,"email":51},"Andreas Klein, MD",{"facility":166,"status":73,"city":153,"state":154,"zip":167,"country":77,"countryCode":78,"cosmosGeoPoint":168,"geoPoint":170,"contacts":51},"Dana-Farber Cancer Institute","02215",{"type":80,"coordinates":169},[158,159],{"lat":159,"lon":158},{"facility":172,"status":73,"city":173,"state":174,"zip":175,"country":77,"countryCode":78,"cosmosGeoPoint":176,"geoPoint":180,"contacts":51},"Barbara Ann Karmanos Cancer Institute (Wayne State University)","Detroit","Michigan","48201",{"type":80,"coordinates":177},[178,179],-83.04575,42.33143,{"lat":179,"lon":178},{"facility":182,"status":97,"city":183,"state":184,"zip":185,"country":77,"countryCode":78,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":80,"coordinates":187},[188,189],-93.26384,44.97997,{"lat":189,"lon":188},[192,193],{"name":108,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":194,"role":111,"phone":51,"phoneExt":51,"email":51},"Supriya Gupta, MD",{"facility":196,"status":73,"city":197,"state":197,"zip":198,"country":77,"countryCode":78,"cosmosGeoPoint":199,"geoPoint":203,"contacts":51},"Weill Cornell Medical College - NY Presbyterian Hospital","New York","10021",{"type":80,"coordinates":200},[201,202],-74.00597,40.71427,{"lat":202,"lon":201},{"facility":205,"status":97,"city":197,"state":197,"zip":206,"country":77,"countryCode":78,"cosmosGeoPoint":207,"geoPoint":209,"contacts":210},"Columbia University Irving Medical Center\u002FNew York Presbyterian Hospital","10032",{"type":80,"coordinates":208},[201,202],{"lat":202,"lon":201},[211,212],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":213,"role":111,"phone":51,"phoneExt":51,"email":51},"Ran Reshef, MD",{"facility":215,"status":73,"city":216,"state":217,"zip":218,"country":77,"countryCode":78,"cosmosGeoPoint":219,"geoPoint":223,"contacts":51},"Duke University","Durham","North Carolina","27708",{"type":80,"coordinates":220},[221,222],-78.89862,35.99403,{"lat":222,"lon":221},{"facility":225,"status":73,"city":226,"state":227,"zip":228,"country":77,"countryCode":78,"cosmosGeoPoint":229,"geoPoint":233,"contacts":51},"Ohio State University","Columbus","Ohio","43210",{"type":80,"coordinates":230},[231,232],-82.99879,39.96118,{"lat":232,"lon":231},{"facility":235,"status":97,"city":236,"state":237,"zip":238,"country":77,"countryCode":78,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"Lifespan Cancer Institute at Rhode Island Hospital","Providence","Rhode Island","02903",{"type":80,"coordinates":240},[241,242],-71.41283,41.82399,{"lat":242,"lon":241},[245,246],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":247,"role":111,"phone":51,"phoneExt":51,"email":51},"Adam Olszewski, MD",{"facility":249,"status":97,"city":250,"state":251,"zip":252,"country":77,"countryCode":78,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"Baylor University Medical Center","Dallas","Texas","75246",{"type":80,"coordinates":254},[255,256],-96.80667,32.78306,{"lat":256,"lon":255},[259,260],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":261,"role":111,"phone":51,"phoneExt":51,"email":51},"Houston Holmes III, MD",{"facility":263,"status":73,"city":264,"state":251,"zip":265,"country":77,"countryCode":78,"cosmosGeoPoint":266,"geoPoint":270,"contacts":51},"MD Anderson","Houston","77030",{"type":80,"coordinates":267},[268,269],-95.36327,29.76328,{"lat":269,"lon":268},{"facility":272,"status":97,"city":273,"state":274,"zip":275,"country":77,"countryCode":78,"cosmosGeoPoint":276,"geoPoint":280,"contacts":281},"Medical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":80,"coordinates":277},[278,279],-87.90647,43.0389,{"lat":279,"lon":278},[282,283],{"name":124,"role":65,"phone":51,"phoneExt":51,"email":51},{"name":284,"role":111,"phone":51,"phoneExt":51,"email":51},"Nirav Shah, MD",{"facility":286,"status":97,"city":287,"state":288,"zip":289,"country":290,"countryCode":291,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"Royal Prince Alfred Hospital","Camperdown","New South Wales","2050","Australia","AU",{"type":80,"coordinates":293},[294,295],151.17642,-33.88965,{"lat":295,"lon":294},[298],{"name":299,"role":65,"phone":51,"phoneExt":51,"email":51},"Dr Vinay Vanguru",{"facility":301,"status":97,"city":302,"state":288,"zip":303,"country":290,"countryCode":291,"cosmosGeoPoint":304,"geoPoint":308,"contacts":309},"Liverpool Hospital","Liverpool","2170",{"type":80,"coordinates":305},[306,307],150.92588,-33.91938,{"lat":307,"lon":306},[310],{"name":311,"role":65,"phone":51,"phoneExt":51,"email":51},"Dr Nagendra P Sungala",{"facility":313,"status":97,"city":314,"state":315,"zip":316,"country":290,"countryCode":291,"cosmosGeoPoint":317,"geoPoint":321,"contacts":322},"Royal Adelaide Hospital","Adelaide","South Australia","5000",{"type":80,"coordinates":318},[319,320],138.59863,-34.92866,{"lat":320,"lon":319},[323],{"name":324,"role":65,"phone":51,"phoneExt":51,"email":51},"Dr Danielle Blunt",{"facility":326,"status":97,"city":327,"state":328,"zip":329,"country":290,"countryCode":291,"cosmosGeoPoint":330,"geoPoint":334,"contacts":335},"St Vincent's Hospital Melbourne","Fitzroy","Victoria","3065",{"type":80,"coordinates":331},[332,333],144.97833,-37.79839,{"lat":333,"lon":332},[336],{"name":337,"role":111,"phone":51,"phoneExt":51,"email":51},"Matthew Ku",{"facility":339,"status":97,"city":340,"state":328,"zip":341,"country":290,"countryCode":291,"cosmosGeoPoint":342,"geoPoint":346,"contacts":347},"Barwon Health - Andrew Love Cancer Centre","Geelong","3320",{"type":80,"coordinates":343},[344,345],144.36069,-38.14711,{"lat":345,"lon":344},[348],{"name":349,"role":111,"phone":51,"phoneExt":51,"email":51},"Hannah Rose",{"type":351,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR","100336867","phase-1-dose-escalation-and-dose-expansion-study-of-safety-of-azer-cel-pbcar0191-in-participants-with-relapsedrefractory-rr-non-hodgkin-lymphoma-nhl-and-rr-b-cell-acute-lymphoblastic-leukemia-b-all-100336867",false,"NCT03666000","Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed\u002FRefractory (r\u002Fr) Non-Hodgkin Lymphoma (NHL) and r\u002Fr B-cell Acute Lymphoblastic Leukemia (B-ALL)","A Phase 1\u002F1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or \"Azer-cel\") in Subjects With Relapsed\u002FRefractory (r\u002Fr) Non-Hodgkin Lymphoma (NHL) and r\u002Fr B-cell Acute Lymphoblastic Leukemia (B-ALL)","Key Inclusion Criteria\n\nCriteria for B-ALL:\n\n• Participant has confirmed unequivocal r\u002Fr CD19+ B-ALL.\n\nCriteria for NHL and CLL\u002FSLL:\n\n• Participant has unequivocal aggressive CD19+ r\u002Fr B-cell NHL that is confirmed by tumor biopsy tissue from last relapse after CD19-directed therapy.\n\nFor Phase 1 Dose Escalation:\n\n* Diffuse large B-cell lymphoma (DLBCL) including Richter's transformation\n* Follicular lymphoma (FL) including Grade 3 or transformed FL\n* High-grade B-cell lymphoma (HGBCL)\n* Primary mediastinal lymphoma\n\nFor Phase 1b Dose Expansion (CAR T-relapsed cohort):\n\n* DLBCL not otherwise specified (NOS)\n* HGBCL\n* DLBCL transformed from the following indolent lymphoma subtypes (FL, Marginal Zone lymphoma \\[MZL\\], and Waldenstrom's Macroglobulinemia \\[WM\\])\n* Other large B-cell lymphoma (LBCL) subtypes may be enrolled with approval from the Medical Monitor.\n* Participants previously treated with CD19-directed autologous CAR T therapies have received no more than 2 lines of therapy after administration of their previous CAR T product.\n* For the expansion CAR T-relapsed cohort only: Participants must have received autologous CD19-directed CAR T therapy and demonstrated clinical response to the treatment at Day 28 or later, followed by relapse or progression.\n\nFor Phase 1b dose expansion (CAR T-naive cohort):\n\n* DLBCL NOS\n* DLBCL transformed from the following indolent lymphoma subtypes (FL, MZL, and WM)\n* HGBCL\n* FL (Grade 1-3a)\n* MZL that is fluorodeoxyglucose (FDG)-avid on positron emission tomography (PET) scan\n* WM\n* CLL\u002FSLL\n* Primary central nervous system (CNS) lymphoma (PCNSL)\n* Other LBCL subtypes may be enrolled with approval from the Medical Monitor.\n* Participant must have received at least 1-2 prior lines of therapy, depending on histological subtype but no more than 7 systemic lines of anti-cancer therapy.\n\nCriteria for both B-ALL, NHL, and CLL\u002FSLL:\n\n* Eastern Cooperative Oncology Group performance status score of 0 or 1.\n* An estimated life expectancy of at least 12 weeks according to the investigator's judgment.\n* Seronegative for human immunodeficiency virus antibody.\n* Participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function.\n\nKey Exclusion Criteria\n\nCriteria for B-ALL:\n\n• Burkitt cell (L3 ALL) or mixed-lineage acute leukemia.\n\nCriteria for NHL:\n\n* Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression.\n* Active hemolytic anemia.\n\nCriteria for B-ALL and NHL:\n\n* No active CNS disease, excluding PCNSL\n* History of another primary malignancy\n* Any form of primary immunodeficiency (for example, severe combined immunodeficiency disease).\n* History of hepatitis B or hepatitis C currently receiving ongoing antiviral therapy.\n\nAny known uncontrolled cardiovascular disease at the time of Screening that, in the investigator's opinion, renders the participant ineligible\n\n* History of hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening.\n* History of severe immediate hypersensitivity reaction to any of the agents used in this study.\n* Presence of a CNS disorder that, in the opinion of the investigator, renders the participant ineligible for treatment.\n* History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or any other known bone marrow failure syndrome.\n* Active uncontrolled autoimmune disease requiring active immunosuppression at the time of Screening (excluding participants needing steroids for physiologic replacement).\n* Participant has received stem cell transplant within 90 days before Screening.\n* Participant has active graft-versus-host disease (GvHD) symptoms.\n* Participant has received a systemic biologic agent for treatment of the disease under study within 28 days of LD, other systemic anti-cancer therapy within 10 days or 5 half-lives (whichever is shorter) of LD, and no pulse steroid for disease control within 3 days of LD.\n* Radiotherapy within 4 weeks before Screening.\n* Presence of pleural\u002Fperitoneal\u002Fpericardial catheter, as well as permeant biliary and ureteral stents (does not apply to intravenous lines).\n* Participant has received live vaccine within 4 weeks before Screening. Note: Non-live virus vaccines are not excluded.\n* Participant has received CD19-directed therapy other than autologous CD19-directed CAR T therapy within 90 days of the anticipated start date of LD.\n\nAdditional criteria apply.","ALL","18 Years",{"count":362,"type":363},135,"ESTIMATED","INTERVENTIONAL",[366],"PHASE1","This is a Phase 1\u002F1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r\u002Fr B ALL, r\u002Fr B-cell NHL and CLL\u002FSLL.",[369,370,371,372],"Non-Hodgkin Lymphoma","B-cell Acute Lymphoblastic Leukemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","2026-01-28",{"date":375,"type":376},"2026-02-02","ACTUAL",{"date":378,"type":376},"2019-03-11",{"date":380,"type":363},"2027-06",{"name":5,"class":6},23]